目的 通过原发性高血压大鼠（spontaneously hypertensive rat,SHR）验证益生菌BPL1（Bifidobacterium animalis subsp. lactis BPL1）降血压的功效并探讨可能机制。方法 将50只SHR随机分为模型对照组、卡托普利阳性对照组、益生菌BPL1高[BPL1(H)]、中[BPL1(M)]、低[BPL1(L)]剂量组,每组10只,并取10只正常血压大鼠(Wistar-Kyoto,WKY)作为空白对照组。连续灌胃30d干预,期间监测大鼠体质量、收缩压（systolic blood pressure,SBP）、舒张压（diastolic blood pressure,DBP）、平均压(mean arterial pressure,MAP)、心率（Heart rate,HR）;实验结束后观察大鼠肾脏病理切片,检测肾脏血管紧张素I转换酶（angiotensin I converting enzyme,ACE）蛋白表达、生化及免疫学相关指标,分析动物肠道菌群构成与变化。结果 BPL1各剂量组SBP均显著低于模型组（P<0.05）;BPL1 (M)、BPL1 (H)组DBP显著低于模型组,且BPL1各剂量组DBP均接近阳性对照组,差异无统计学意义;BPL1各剂量组MAP显著低于模型组（P<0.05）;BPL1 (L)、BPL1 (H)组干预后血管紧张素Ⅱ（angiotensin II,AngⅡ）显著低于模型组（P<0.05）;BPL1各剂量组醛固酮（aldosterone,ALD）水平显著低于模型组（P<0.05）;BPL1 (L)干预后免疫球蛋白A（immunoglobulin A,IgA）的水平显著高于模型组（P<0.05）;BPL1各剂量组干预后主动脉肿瘤坏死因子-α（tumor necrosis factor-α,TNF-α）的水平较模型组有显著的降低,BPL1 (M) 干预后主动脉白细胞介素-1（interleukin-6,IL-1β）显著低于模型组（P<0.05）;BPL1各剂量组的ACE蛋白表达量的均值均低于模型组;BPL1各剂量组的厚壁菌门和拟杆菌门的比值F/B值的均数均低于模型组,并且随着BPL1剂量的升高存在下降的趋势。结论 益生菌BPL1的降压效果可能是通过影响机体的肾素-血管紧张素-醛固酮系统,抑制ACE活性,限制Ang II转化途径,同时恢复肠道菌群的平衡来实现。
Abstract
Objective To verify the effect of Bifidobacterium animalis subsp. lactis (BPL1) on blood pressure in spontaneously hypertensive rats (SHR) and to explore the possible mechanisms. Methods Fifty SHR rats were randomly divided into model control group (MC), captopril positive control group (PC), probiotic BPL1 high-dose [BPL1(H)], medium-dose [BPL1(M)] and low-dose groups [BPL1(L)] with 10 rats in each group. Ten Wistar-Kyoto (WKY) rats were selected as blank control group. Body mass, systolic blood pressure (SBP), diastolic blood pressure (DBP), mean arterial pressure (MAP) and heart rate were monitored during 30 days. After the experiment, the pathological sections of rat kidney were observed and the expression of renal angiotensin I converting enzyme (ACE) protein, biochemical and immunological related indexes, and the composition and changes of intestinal flora were analyzed. Results The SBP of the BPL1 dose groups was significantly lower than that of the model group (P<0.05). The DBP of the BPL1(M) and BPL1(H) groups was significantly lower than that in the model group, and the DBP of the BPL1 dose groups was close to the positive control group. However, the difference was not statistically significant. The MAP of the BPL1 dose groups was significantly lower than that of model group (P<0.05). Serum angiotensin II (AngⅡ )in the BPL1(L) and BPL1(H) groups was significantly lower than that in the model group (P<0.05). The level of aldosterone (ALD) in the BPL1 dose groups was significantly lower than that in the model group (P<0.05). The level of immunoglobulin A (IgA) in the BPL1(L) group was significantly higher than that in the model group (P<0.05). The level of tumor necrosis factor-α (TNF-α) in aorta after BPL1(M) treatment was significantly lower than that in the model group, and the level of interleukin-1β (IL-1β) in aorta after BPL1(M) treatment was significantly lower than that in the model group (P<0.05). The kidney expression of ACE protein in BPL1 dose groups was lower than that in the model group. The average F/B ratio in BPL1 dose groups was lower than that in the model group, and there was a downward trend with the increase of BPL1 dose. Conclusion Probiotic BPL1 has a remarkable antihypertensive effect by affecting renin-angiotensin-aldosterone system, inhibiting angiotensin I converting enzyme (ACE) activity, restricting Ang II conversion pathway, and restoring the balance of intestinal flora.
关键词
益生菌BPL1 /
高血压 /
血管紧张素I转换酶 /
血管紧张素II /
醛固酮 /
肠道菌群
Key words
Bifidobacterium animalis subsp. lactis (BPL1) /
hypertension /
angiotensin I converting enzyme /
angiotensin II /
aldosterone /
intestinal flora
{{custom_sec.title}}
{{custom_sec.title}}
{{custom_sec.content}}
参考文献
[1] Mammi C, Pastore D, Lombardo MF, et al. Sildenafil reduces insulin-resistance in human endothelial cells[J]. PLoS One, 2011, 6: e14542.
[2] Oparil S, Acelajado MC, Bakris GL, et al. Hypertension[J]. Nat Rev Dis Primers, 2018, 4: 1–21.
[3] Te Riet L, van Esch JHM, Roks AJM, et al. Hypertension: renin-angiotensin-aldosterone system alterations[J]. Circ Res, 2015, 116: 960-975.
[4] Jama HA, Kaye DM, Marques FZ.The gut microbiota and blood pressure in experimental models[J]. Curr Opin Nephrol Hypertens, 2019, 28: 97–104.
[5] Li J, Zhao F, Wang Y, et al. Gut microbiota dysbiosis contributes to the development of hypertension[J]. Microbiome, 2017, 5: 1–19.
[6] Nakamura Y, Yamamoto N, Sakai K, et al. Antihypertensive effect of sour milk and peptides isolated from it that are inhibitors to angiotensin I-converting enzyme[J]. J Dairy Sci, 1995, 78: 1253–1257.
[7] Lee HA, Cho HM, Lee DY, et al. Tissue-specific upregulation of angiotensin-converting enzyme 1 in spontaneously hypertensive rats through histone code modifications[J]. Hypertension, 2012, 59: 621–626.
[8] Sipola M, Finckenberg P, Korpela R, et al. Effect of long-term intake of milk products on blood pressure in hypertensive rats[J]. J Dairy Res, 2002, 69: 103–111.
[9] 黄文利, 陈卫, 田丰伟, 等. 干酪乳杆菌 LC-15 发酵乳血管紧张素转换酶体外抑制活性的研究[J]. 食品研究与开发, 2006, 27: 17–21.
[10] Chen Y, Liu W, Xue J, et al. Angiotensin-converting enzyme inhibitory activity of Lactobacillus helveticus strains from traditional fermented dairy foods and antihypertensive effect of fermented milk of strain H9[J]. J Dairy Sci, 2014, 97: 6680–6692.
[11] 郑晗盈, 兰慧, 庄滢滢, 等. 动物双歧杆菌和罗伊氏乳杆菌改善肥胖小鼠糖脂代谢异常的研究[J]. 营养学报, 2021, 43: 283–288.
[12] Pedret A, Valls RM, Calderón-Pérez L, et al. Effects of daily consumption of the probiotic Bifidobacterium animalis subsp. lactis CECT 8145 on anthropometric adiposity biomarkers in abdominally obese subjects: a randomized controlled trial[J]. Int J Obes, 2019, 43: 1863–1868.
[13] 王蕾,尚倩倩,张叶青等.原发性高血压患者脉象参数与心脏自主神经功能指标的典型相关分析[J].时珍国医国药,2019,30:2760–2762.
[14] Drummond GR, Vinh A, Guzik TJ, et al. Immune mechanisms of hypertension[J]. Nat Rev Immunol, 2019, 19: 517–532.
[15] Dingwell LS, Shikatani EA, Besla R, et al. B-cell deficiency lowers blood pressure in mice[J]. Hypertension 2019, 73: 561–570.
[16] Saha P, Mell B, Golonka RM, et al. Selective IgA deficiency in spontaneously hypertensive rats with gut dysbiosis[J]. Hypertension, 2022, 79: 2239–2249.
[17] 侯翠柳,陈东,来松,等.自然杀伤T细胞在血管紧张素Ⅱ诱导的高血压中的作用[J].心肺血管病杂志,2018,37:72–75.
[18] Kohan DE, Merli CA, Simon EE.Micropuncture localization of the natriuretic effect of interleukin 1[J]. Am J Physiol, 1989, 256: F810–F813.
[19] Shahid M, Francis J, Majid DSA.Tumor necrosis factor-α induces renal vasoconstriction as well as natriuresis in mice[J]. Am J Physiol Rena Physiol, 2008, 295: F1836–F1844.
[20] Rucker AJ, Crowley SD.The role of macrophages in hypertension and its complications[J]. Pflugers Arch, 2017, 469: 419–430.
[21] Atlas SA.The renin-angiotensin aldosterone system: pathophysiological role and pharmacologic inhibition[J]. J Manag Care Pharm, 2007, 13(8 Supp B): 9–20.
[22] Johnston CI.Renin-angiotensin system: a dual tissue and hormonal system for cardiovascular control[J]. J Hypertens,1992, 10: S27.
[23] Xue L, Yin R, Howell K, et al. Activity and bioavailability of food protein-derived angiotensin-I-converting enzyme-inhibitory peptides[J]. Compr Rev Food Sci Food Saf, 2021, 20: 1150–1187.
[24] Larabi A, Barnich N, Nguyen HTT.New insights into the interplay between autophagy, gut microbiota and inflame- matory responses in IBD[J]. Autophagy, 2020, 16: 38–51.
[25] Sircana A, De Michieli F, Parente R, et al. Gut microbiota, hypertension and chronic kidney disease: recent advances[J]. Pharmacol Res, 2019, 144: 390–408.
[26] Karbach SH, Schönfelder T, Brandão I, et al. Gut microbiota promote angiotensin II-induced arterial hypertension and vascular dysfunction[J]. J Am Heart Assoc, 2016, 5: e003698.
[27] Yang T, Santisteban MM, Rodriguez V, et al. Gut dysbiosis is linked to hypertension[J]. Hypertension, 2015, 65: 1331–1340.
